Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

Autor: Othon Iliopoulos, Rodolfo F. Perini, Vivek Narayan, Jodi K. Maranchie, Sarah J. Welsh, Frede Donskov, Eric Jonasch, Stéphane Oudard, Sanjay Thamake, Benjamin L. Maughan, Mk Investigators, Eric Kristopher Park, Tobias Else, W. Kimryn Rathmell, Ramaprasad Srinivasan, W. Marston Linehan

Publikováno v: Jonasch, E, Donskov, F, Iliopoulos, O, Rathmell, W K, Narayan, V K, Maughan, B L, Oudard, S, Else, T, Maranchie, J K, Welsh, S J, Thamake, S, Park, E K, Perini, R F, Linehan, W M, Srinivasan, R & the MK-6482-004 Investigators 2021, ' Belzutifan for renal cell carcinoma in von Hippel-Lindau disease ', New England Journal of Medicine, vol. 385, no. 22, pp. 2036-2046 . https://doi.org/10.1056/NEJMoa2103425
N Engl J Med

BACKGROUND: Patients with von Hippel–Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS: In this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1438610bde404348fe5c3a5618e91497
https://doi.org/10.1056/nejmoa2103425